Seaport Therapeutics, Inc. (Ticker: SPTX US) is a US-registered clinical-stage therapeutics company focused on developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Seaport Therapeutics plans to list on the NASDAQ exchange following its scheduled pricing on April 30, 2026. The company is planning to offer 11,800,000 primary shares at an estimated price range of $16.00 to $18.00 per share, targeting an overall IPO offer size of approximately $200 million.

According to published terms, the shares filed represent a 100 percent primary offering. The company utilizes a differentiated approach to identify clinically validated mechanisms with established efficacy and safety profiles that were historically limited by high first-pass metabolism or low bioavailability. To overcome these limitations, Seaport Therapeutics applies its proprietary Glyph platform to invent innovative oral therapies. As reported in the preliminary terms, the IPO features Goldman Sachs, J.P. Morgan, Leerink, Citi, and Stifel as lead bookrunners, with J.P. Morgan acting as the stabilization agent.